Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease

Affiliations

• ¹ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia. d.finkelstein@florey.edu.au.
• ² The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
• ³ Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
• ⁴ The Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.
• ⁵ Elemental Bio-Imaging Facility, The University of Technology Sydney, Broadway, Ultimo, NSW, 2007, Australia.
• ⁶ Australia Electron Microscope Unit, School of Biosciences, The University of Melbourne, Melbourne, VIC, 3010, Australia.
• ⁷ Prana Biotechnology Ltd, Parkville, VIC, 3052, Australia.
• ⁸ Bio21 Institute and Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, VIC, 3010, Australia.
• ⁹ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, 3010, Australia. rcherny@unimelb.edu.au.
• ¹⁰ Prana Biotechnology Ltd, Parkville, VIC, 3052, Australia. rcherny@unimelb.edu.au.